Oncology Department, Institut Jules Bordet, and Université Libre de Bruxelles (U.L.B), Brussels, Belgium.
Centre for Cancer Immunotherapy, Oncology Department, INSERM U932, Institut Curie, PSL Research University, Paris, France.
Ann Oncol. 2021 Mar;32(3):323-336. doi: 10.1016/j.annonc.2020.11.022. Epub 2020 Dec 9.
Immunotherapy emerged as a new treatment modality for breast cancer, and its use is approved in combination with chemotherapy for first-line therapy in metastatic triple-negative breast cancer overexpressing PD-L1. As immune checkpoint inhibitors alone have modest clinical activity in advanced breast cancer, there is a growing interest in combinatorial modalities, and particularly for their rapid development in the early disease setting. The plethora of ongoing immunotherapy trials in early breast cancer comes at a time when solid data in advanced disease are still imperfect. This review offers a perspective on the efforts to establish the efficacy and safety of immunotherapeutic agents in early breast cancer.
免疫疗法成为乳腺癌的一种新治疗方式，其与化疗联合用于 PD-L1 过表达的转移性三阴性乳腺癌的一线治疗已获得批准。由于免疫检查点抑制剂在晚期乳腺癌中的临床活性有限，因此人们对联合治疗方法越来越感兴趣，特别是在早期疾病治疗中。大量正在进行的早期乳腺癌免疫治疗试验是在晚期疾病中仍存在不完善的可靠数据的情况下进行的。本文综述了在早期乳腺癌中确定免疫治疗药物疗效和安全性的努力。
